Drug Profile
Research programme: capsid assembly inhibitors - Arbutus Biopharma
Alternative Names: ARB-168786; ARB-1820; ARB-880; Core protein inhibitors - ArbutusLatest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Baruch S. Blumberg Institute; Drexel University College of Medicine; Enantigen Therapeutics
- Developer Arbutus Biopharma
- Class Antivirals; Small molecules
- Mechanism of Action Capsid protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Hepatitis-B in USA (PO)
- 06 Nov 2019 Preclinical development for Hepatitis B is ongoing in USA
- 28 Oct 2018 No recent reports of development identified for preclinical development in Hepatitis-B in USA (PO)